<DOC>
	<DOC>NCT00635323</DOC>
	<brief_summary>To evaluate the safety and efficacy of irinotecan and capecitabine in Asian subjects with inoperable hepatocellular carcinoma.</brief_summary>
	<brief_title>Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Asian subjects with histologically or cytologically confirmed hepatocellular carcinoma Inoperable disease (unable to completely remove surgically, presence of extrahepatic disease, main portal vein or hepatic vein involvement) Eastern Cooperative Oncology Group performance status of ?2 Decompensated cirrhosis or stage C (Index&gt;10) according to the ChildPugh Classification Current history of chronic diarrhoea Reproductive potential not using adequate contraceptive measures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>